	US 12,357,579 B2
	Capsule for treating ulcerative colitis
Takanori Kanai, Tokyo (JP); Hideo Nishimura, Kobe (JP); Tomoyuki Koyama, Hirakata (JP); Takuhiko Adachi, Hirakata (JP); and Hiroyuki Hayakawa, Hirakata (JP)
Assigned to KEIO UNIVERSITY, Tokyo (JP); FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE, Kobe (JP); and MORISHITA JINTAN CO., LTD., Osaka (JP)
Filed by KEIO UNIVERSITY, Tokyo (JP); Foundation for Biomedical Research and Innovation at Kobe, Kobe (JP); and MORISHITA JINTAN CO., LTD., Osaka (JP)
Filed on May 2, 2023, as Appl. No. 18/310,999.
Application 18/310,999 is a division of application No. 16/962,968, abandoned, previously published as PCT/JP2019/001002, filed on Jan. 16, 2019.
Claims priority of application No. 2018-006659 (JP), filed on Jan. 18, 2018.
Prior Publication US 2023/0263740 A1, Aug. 24, 2023
Int. Cl. A61K 9/48 (2006.01); A61K 31/404 (2006.01); A61P 1/04 (2006.01)

CPC A61K 9/4891 (2013.01) [A61K 9/4866 (2013.01); A61K 9/4875 (2013.01); A61K 31/404 (2013.01); A61P 1/04 (2018.01)]

12 Claims

1. A method for treating ulcerative colitis, comprising

orally administering to a subject a capsule that comprises indigo and a substance adherable to the epithelium of the large intestine, and

adhering indigo, in an amount effective for treating ulcerative colitis, to an epithelium of a large intestine of the subject in the presence of the substance adherable to the epithelium of the large intestine, wherein

the substance adherable to the epithelium of the large intestine is fat-soluble tocopherol,

an amount of the fat-soluble tocopherol falls within the range of 0.5 to 40% by mass of the whole capsule, and

the indigo acts as an active agent for the treating of the ulcerative colitis.